SG Americas Securities LLC lifted its position in Incyte Corporation (NASDAQ:INCY) by 167.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 83,590 shares of the biopharmaceutical company’s stock after purchasing an additional 52,291 shares during the quarter. SG Americas Securities LLC’s holdings in Incyte Corporation were worth $9,758,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Cornerstone Advisors Inc. lifted its position in Incyte Corporation by 19.6% during the 2nd quarter. Cornerstone Advisors Inc. now owns 884 shares of the biopharmaceutical company’s stock worth $111,000 after acquiring an additional 145 shares during the period. Tower Research Capital LLC TRC lifted its position in Incyte Corporation by 13.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 108 shares during the period. Seven Eight Capital LP acquired a new stake in Incyte Corporation during the 2nd quarter worth approximately $129,000. IFP Advisors Inc lifted its position in Incyte Corporation by 9.9% during the 2nd quarter. IFP Advisors Inc now owns 1,146 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 103 shares during the period. Finally, Sun Life Financial INC lifted its position in Incyte Corporation by 9,069.2% during the 2nd quarter. Sun Life Financial INC now owns 1,192 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 1,179 shares during the period. 89.53% of the stock is owned by institutional investors.

A number of research firms have weighed in on INCY. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating and set a $135.00 price objective on shares of Incyte Corporation in a research report on Thursday, August 31st. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $149.00 price objective on shares of Incyte Corporation in a research report on Thursday, August 31st. BMO Capital Markets reaffirmed a “buy” rating and set a $172.00 price objective on shares of Incyte Corporation in a research report on Friday, July 21st. Jefferies Group LLC reaffirmed a “buy” rating and set a $148.00 price objective on shares of Incyte Corporation in a research report on Thursday, July 27th. Finally, Raymond James Financial, Inc. raised Incyte Corporation from a “market perform” rating to an “outperform” rating and set a $159.00 price objective for the company in a research report on Monday, September 11th. Seven investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Incyte Corporation has a consensus rating of “Buy” and an average price target of $144.98.

Incyte Corporation (NASDAQ INCY) traded up $0.25 during trading on Friday, reaching $106.73. The company’s stock had a trading volume of 361,511 shares, compared to its average volume of 1,770,000. The company has a quick ratio of 4.81, a current ratio of 4.82 and a debt-to-equity ratio of 0.01. Incyte Corporation has a one year low of $98.49 and a one year high of $153.15.

Incyte Corporation (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.11. The company had revenue of $381.50 million during the quarter, compared to the consensus estimate of $360.34 million. Incyte Corporation had a negative return on equity of 12.91% and a negative net margin of 10.90%. Incyte Corporation’s revenue was up 41.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.19 earnings per share. research analysts anticipate that Incyte Corporation will post -1.3 EPS for the current year.

In other news, insider David W. Gryska sold 3,915 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $105.63, for a total transaction of $413,541.45. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Bros. Advisors Lp Baker acquired 100,000 shares of the firm’s stock in a transaction dated Friday, September 8th. The shares were acquired at an average price of $132.00 per share, for a total transaction of $13,200,000.00. The disclosure for this purchase can be found here. Insiders have sold 102,062 shares of company stock valued at $12,652,893 in the last three months. 17.70% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Incyte Corporation (INCY) Shares Bought by SG Americas Securities LLC” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/11/17/incyte-corporation-incy-shares-bought-by-sg-americas-securities-llc.html.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY).

Institutional Ownership by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Stock Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related stocks with our FREE daily email newsletter.